OBJECTIVES: The aim of the study was to examine trends in initiating highly active antiretroviral therapy (HAART) with a CD4 count ≤ 200 cells/μL and the contribution of having a CD4 count ≤ 200 cells/μL at the time of diagnosis to these trends, in British Columbia (BC), Canada. METHODS: We included in the analysis treatment-naïve BC residents aged ≥ 19 years who initiated HAART from 2003 to 2012. Participants were classified as follows: Group 1: diagnosed and initiated HAART with a CD4 count > 200 cells/μL; Group 2: diagnosed with a CD4 count > 200 cells/μL and initiated HAART with a CD4 count ≤ 200 cells/μL; and Group 3: diagnosed and initiated HAART with a CD4 count ≤ 200 cells/μL. We measured trends in initiating HAART with a CD4 count ≤ 200 cells/μL and used logistic regression models to measure factors associated with initiating HAART with a CD4 count ≤ 200 cells/μL, stratified by having a CD4 count ≤ 200 cells/μL or > 200 cells/μL at the time of diagnosis. RESULTS: Between 2003 and 2012, 3506 BC residents initiated HAART. Of these, 44% (1558 of 3506) initiated HAART with a CD4 count ≤ 200 cells/μL. This proportion declined from 69% (198 of 287) in 2003 to 21% (81 of 330) in 2012 (P < 0.001). The proportion of those in Group 3 increased from 49% (97 of 198) in 2003 to 69% (56 of 81) in 2012 (P < 0.001). Overall, 56% (1948), 22% (776) and 22% (782) made up Groups 1, 2, and 3, respectively. In adjusted analyses, seeing a specialist was significantly associated with being in Group 3. Using injection drugs and seeing a specialist were associated with being in Group 2. CONCLUSIONS: In recent years, among individuals who ever initiated HAART in BC, being diagnosed with low CD4 cell counts has become a greater contributor to initiating HAART with low CD4 cell counts.
OBJECTIVES: The aim of the study was to examine trends in initiating highly active antiretroviral therapy (HAART) with a CD4 count ≤ 200 cells/μL and the contribution of having a CD4 count ≤ 200 cells/μL at the time of diagnosis to these trends, in British Columbia (BC), Canada. METHODS: We included in the analysis treatment-naïve BC residents aged ≥ 19 years who initiated HAART from 2003 to 2012. Participants were classified as follows: Group 1: diagnosed and initiated HAART with a CD4 count > 200 cells/μL; Group 2: diagnosed with a CD4 count > 200 cells/μL and initiated HAART with a CD4 count ≤ 200 cells/μL; and Group 3: diagnosed and initiated HAART with a CD4 count ≤ 200 cells/μL. We measured trends in initiating HAART with a CD4 count ≤ 200 cells/μL and used logistic regression models to measure factors associated with initiating HAART with a CD4 count ≤ 200 cells/μL, stratified by having a CD4 count ≤ 200 cells/μL or > 200 cells/μL at the time of diagnosis. RESULTS: Between 2003 and 2012, 3506 BC residents initiated HAART. Of these, 44% (1558 of 3506) initiated HAART with a CD4 count ≤ 200 cells/μL. This proportion declined from 69% (198 of 287) in 2003 to 21% (81 of 330) in 2012 (P < 0.001). The proportion of those in Group 3 increased from 49% (97 of 198) in 2003 to 69% (56 of 81) in 2012 (P < 0.001). Overall, 56% (1948), 22% (776) and 22% (782) made up Groups 1, 2, and 3, respectively. In adjusted analyses, seeing a specialist was significantly associated with being in Group 3. Using injection drugs and seeing a specialist were associated with being in Group 2. CONCLUSIONS: In recent years, among individuals who ever initiated HAART in BC, being diagnosed with low CD4 cell counts has become a greater contributor to initiating HAART with low CD4 cell counts.
Authors: Sophie Patterson; Angela Cescon; Hasina Samji; Zishan Cui; Benita Yip; Katherine J Lepik; David Moore; Viviane D Lima; Bohdan Nosyk; P Richard Harrigan; Julio S G Montaner; Kate Shannon; Evan Wood; Robert S Hogg Journal: Int J Epidemiol Date: 2014-03-17 Impact factor: 7.196
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Melanie A Thompson; Judith A Aberg; Jennifer F Hoy; Amalio Telenti; Constance Benson; Pedro Cahn; Joseph J Eron; Huldrych F Günthard; Scott M Hammer; Peter Reiss; Douglas D Richman; Giuliano Rizzardini; David L Thomas; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2012-07-25 Impact factor: 56.272
Authors: José A Pérez-Molina; Marta Díaz-Menéndez; María N Plana; Javier Zamora; Rogelio López-Vélez; Santiago Moreno Journal: J Antimicrob Chemother Date: 2011-11-29 Impact factor: 5.790
Authors: J A Pérez-Molina; I Suárez-Lozano; A Del Arco; R Teira; P Bachiller; E Pedrol; E Martínez-Alfaro; P Domingo; A Mariño; E Ribera; A Antela; J de Otero; V Navarro; Juan González-García Journal: HIV Clin Trials Date: 2011 Jan-Feb
Authors: Heidi Spillane; Sarala Nicholas; Zhirong Tang; Elisabeth Szumilin; Suna Balkan; Mar Pujades-Rodriguez Journal: Trop Med Int Health Date: 2012-08-05 Impact factor: 2.622
Authors: Margaret May; Mark Gompels; Valerie Delpech; Kholoud Porter; Frank Post; Margaret Johnson; David Dunn; Adrian Palfreeman; Richard Gilson; Brian Gazzard; Teresa Hill; John Walsh; Martin Fisher; Chloe Orkin; Jonathan Ainsworth; Loveleen Bansi; Andrew Phillips; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin Journal: BMJ Date: 2011-10-11
Authors: Julio S G Montaner; Viviane D Lima; P Richard Harrigan; Lillian Lourenço; Benita Yip; Bohdan Nosyk; Evan Wood; Thomas Kerr; Kate Shannon; David Moore; Robert S Hogg; Rolando Barrios; Mark Gilbert; Mel Krajden; Reka Gustafson; Patricia Daly; Perry Kendall Journal: PLoS One Date: 2014-02-12 Impact factor: 3.240
Authors: Hasina Samji; Angela Cescon; Robert S Hogg; Sharada P Modur; Keri N Althoff; Kate Buchacz; Ann N Burchell; Mardge Cohen; Kelly A Gebo; M John Gill; Amy Justice; Gregory Kirk; Marina B Klein; P Todd Korthuis; Jeff Martin; Sonia Napravnik; Sean B Rourke; Timothy R Sterling; Michael J Silverberg; Stephen Deeks; Lisa P Jacobson; Ronald J Bosch; Mari M Kitahata; James J Goedert; Richard Moore; Stephen J Gange Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Angela Cescon; Sophie Patterson; Colin Davey; Erin Ding; Janet M Raboud; Keith Chan; Mona R Loutfy; Curtis Cooper; Ann N Burchell; Alexis K Palmer; Christos Tsoukas; Nima Machouf; Marina B Klein; Sean B Rourke; Anita Rachlis; Robert S Hogg; Julio S G Montaner Journal: J Int AIDS Soc Date: 2015-10-05 Impact factor: 5.396